Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 100
Filter
1.
J Eur Acad Dermatol Venereol ; 34(1): 135-141, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31301682

ABSTRACT

BACKGROUND: Atopic dermatitis (AD) is one of the most common chronic inflammatory diseases of the skin. Rare large-scale data have been published on the prevalence of concomitant dermatoses. OBJECTIVE: To analyse the prevalence and cutaneous comorbidity of AD in Germany. METHODS: A cross-sectional study on voluntary whole-body skin checks by trained dermatologists in over 400 companies throughout Germany reflecting the adult working population was conducted. Prevalence ratios (PR) were calculated to compare dermatological comorbidity in employees with and without current AD. A logistic regression analysis controlling for age, sex and skin type revealed odds ratios (OR) of the occurrence of skin diseases in AD. RESULTS: A total of N = 118 939 people were examined between 2006 and 2017 (43.2% female, mean age 43.2 ± 10.7 years, min. age 16 years, max. age 70 years). AD (point prevalence) was identified in 1.45% (men: 1.50%, women 1.39%) and decreased significantly with age. Self-reported lifetime prevalence of AD was 4.95% (men: 3.72%, women: 6.55%). The following skin diseases were significantly more frequent in people with current AD: Contact dermatitis (PR: 3.38), hand eczema (PR: 4.62), exsiccation dermatosis (PR: 2.19), folliculitis (PR: 1.95) and port-wine stains (PR: 1.49). Among those, folliculitis was the most frequent (prevalence in AD 16.42%). Controlled for age, sex and skin type, AD was significantly associated with - among others - hand eczema (OR: 3.96; 95% CI: 2.95-5.32), contact dermatitis (OR: 2.97; 95% CI: 1.50-5.88) and exsiccation dermatosis (OR: 1.78; 95% CI: 1.30-2.44). Psoriasis was significantly less frequent in people with AD (OR: 0.61; 95% CI: 0.39-0.94). CONCLUSION: In summary, cutaneous comorbidity is frequent and of great importance in people with AD, suggesting the need for comprehensive, dermatologically guided diagnostics in AD.


Subject(s)
Dermatitis, Atopic/complications , Dermatitis, Atopic/epidemiology , Adolescent , Adult , Aged , Cohort Studies , Cross-Sectional Studies , Dermatitis, Atopic/diagnosis , Female , Germany , Humans , Logistic Models , Male , Middle Aged , Prevalence , Self Report , Young Adult
2.
Br J Dermatol ; 181(4): 743-748, 2019 10.
Article in English | MEDLINE | ID: mdl-30802934

ABSTRACT

BACKGROUND: Seborrhoeic dermatitis is a common but epidemiologically poorly researched chronic skin disease. OBJECTIVES: To characterize the prevalence and dermatological comorbidity of seborrhoeic dermatitis in Germany. METHODS: In the course of voluntary company skin checks, full-body examinations were carried out in more than 500 companies by experienced dermatologists and documented electronically. RESULTS: In total, 161 269 participants were included (men 55·5%, mean age 43·2 ± 10·9 years). Seborrhoeic dermatitis was identified in 3·2% (men 4·6%, women 1·4%). A significant difference was found between age groups (2·0% in < 35; 3·6% in 35-64; 4·4% ≥ 65 years). The most frequent concomitant skin conditions were: folliculitis [17·0%, 95% confidence interval (CI) 15·9-18·1], onychomycosis (9·1%, 95% CI 8·3-10·0), tinea pedis (7·1%, 95% CI 6·3-7·8), rosacea (4·1%, 95% CI 3·6-4·7), acne (4·0%, 95% CI 3·4-4·5) and psoriasis (2·7%, 95% CI 2·3-3·2). Regression analysis revealed the following relative dermatological comorbidities when controlling for age and sex: folliculitis [odds ratio (OR) 2·1, 95% CI 2·0-2·3], contact dermatitis (OR 1·8, 95% CI 1·1-2·8), intertriginous dermatitis (OR 1·8, 95% CI 1·4-2·2), rosacea (OR 1·6, 95% CI 1·4-1·8), acne (OR 1·4, 95% CI 1·2-1·7), pyoderma (OR 1·4, 95% CI 1·1-1·8), tinea corporis (OR 1·4, 95% CI 1·0-2·0), pityriasis versicolor (OR 1·3, 95% CI 1·0-1·7) and psoriasis (OR 1·2, 95% CI 1·0-1·5). CONCLUSIONS: Seborrhoeic dermatitis is a common disease, which is more prevalent in men and older people, and it has an increased rate of dermatological comorbidity. However, absolute differences in the prevalence of comorbidities are small and negligible. Nevertheless, the findings underline the need for integrated, complete dermatological diagnostics and therapy.


Subject(s)
Dermatitis, Seborrheic/epidemiology , Adolescent , Adult , Age Factors , Aged , Cohort Studies , Comorbidity , Dermatitis, Seborrheic/diagnosis , Female , Germany/epidemiology , Humans , Male , Middle Aged , Prevalence , Risk Factors , Sex Factors , Young Adult
3.
Eur J Clin Microbiol Infect Dis ; 34(1): 19-31, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25149825

ABSTRACT

Individuals <2 years and ≥ 50 years of age, as well as those with other specific risk factors, are especially vulnerable to invasive pneumococcal disease (IPD). Conjugate vaccines have been developed against encapsulated bacteria such as Streptococcus pneumoniae to provide improved immune responses. The 7-valent pneumococcal conjugate vaccine (PCV7) has significantly reduced the burden of vaccine-type pneumococcal diseases in children, including invasive disease and pneumonia and acute otitis media. There have also been significant declines in antimicrobial resistance in 7-valent vaccine serotypes and carriage of S. pneumoniae in the post-PCV7 era. Two to three years after the introduction of PCV13, there is emerging, global evidence of a reduced burden of pneumococcal diseases in children, including declines in IPD (UK and Germany) and nasopharyngeal carriage of PCV13 serotypes (Portugal and France). The functional immunogenicity of PCV13 in individuals ≥ 50 years of age has been demonstrated in clinical trials in comparison with the 23-valent pneumococcal polysaccharide vaccine and for children and adults 6 to 49 years of age. Between 2011 and 2013, PCV13 received market authorisation by the European Medicines Agency (EMA) for these additional age groups and is now available in Europe for the prevention of pneumococcal disease in all age groups.


Subject(s)
Carrier State/epidemiology , Carrier State/prevention & control , Pneumococcal Infections/epidemiology , Pneumococcal Infections/prevention & control , Pneumococcal Vaccines/immunology , Streptococcus pneumoniae/classification , Europe/epidemiology , Heptavalent Pneumococcal Conjugate Vaccine , Humans , Nasopharynx/microbiology , Pneumococcal Vaccines/administration & dosage , Prevalence , Streptococcus pneumoniae/isolation & purification , Vaccination/statistics & numerical data
5.
Eur J Clin Microbiol Infect Dis ; 33(11): 2035-40, 2014 Nov.
Article in English | MEDLINE | ID: mdl-24930041

ABSTRACT

Continuous nationwide surveillance of invasive pneumococcal disease (IPD) was conducted in Germany. From July 1, 1997, to June 30, 2013, data on penicillin susceptibility were available for 20,437 isolates. 2,790 of these isolates (13.7 %) originate from patients with meningitis and 17,647 isolates (86.3 %) are from non-meningitis cases. A slight decline in isolates susceptible at 0.06 and 0.12 µg/ml can be noticed over the years. Overall, 89.1 % of the isolates had minimum inhibitory concentrations (MICs) of ≤0.015 µg/ml. In 2012/2013, the first three isolates of Streptococcus pneumoniae with MICs of 8 µg/ml were found. The application of different guidelines with other MIC breakpoints for the interpretation of penicillin resistance leads to differences in susceptibility categorisation. According to the pre-2008 Clinical and Laboratory Standards Institute (CLSI) interpretive criteria, 5.3 % of isolates overall were intermediate and 1.4 % were resistant to penicillin. Application of the 2008-2014 CLSI interpretive criteria resulted in 7.6 % resistance among meningitis cases and 0.5 % intermediate resistance in non-meningitis cases. Referring to the 2009-2014 European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints, 7.6 % of the isolates in the meningitis group were resistant to penicillin. In the non-meningitis group, 6.1 % of the isolates were intermediate and 0.5 % were resistant. These differences should be kept in mind when surveillance studies on pneumococcal penicillin resistance are compared.


Subject(s)
Anti-Bacterial Agents/pharmacology , Penicillins/pharmacology , Pneumococcal Infections/microbiology , Streptococcus pneumoniae/drug effects , Drug Resistance, Bacterial , Germany , Humans , Microbial Sensitivity Tests/standards , Prevalence , Streptococcus pneumoniae/isolation & purification
6.
J Infect ; 61(6): 484-91, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20875454

ABSTRACT

OBJECTIVES: Immune response to many vaccinations is impaired in human immunodeficiency virus (HIV) positive patients. METHODS: A total of n = 131 HIV positive patients were vaccinated against influenza, pneumococcal disease, hepatitis A and B, with n = 82 patients (62.6%) receiving 2 or more simultaneous vaccinations. Safety and immunogenicity of simultaneous vaccinations were assessed. Current antiretroviral therapy (ART) regimens were evaluated as potential predictors for antibody response. RESULTS: Immune response rates were 45% (influenza), 68% (pneumococcus), 63.6% (hepatitis A) and 62.5% (hepatitis B). Adverse reactions after vaccination were documented in 2 of 131 patients (1.5%). No statistically significant difference between pre- and post-vaccination CD4+ T-cell counts (CD4) and HIV plasma load was observed. 85% of patients received ART containing nucleotide reverse transcriptase inhibitors, non-nucleotide reverse transcriptase inhibitors and/or protease inhibitors (PI). Higher ratio of CD4 to CD8 and intake of PI were statistically significant, independent predictors for antibody response after influenza vaccination (OR 1.9 and 2.8, p = 0.01 and 0.04, respectively). CONCLUSIONS: Simultaneous vaccinations in HIV positive patients were safe and well tolerated. The positive effect of PI on antibody response after influenza vaccination should be confirmed in larger studies.


Subject(s)
Antiretroviral Therapy, Highly Active/methods , HIV Infections/drug therapy , HIV Infections/immunology , Hepatitis A Vaccines/immunology , Hepatitis B Vaccines/immunology , Influenza Vaccines/immunology , Pneumococcal Vaccines/immunology , Adolescent , Adult , Aged , Antibodies, Bacterial/blood , Antibodies, Viral/blood , CD4 Lymphocyte Count , CD4-CD8 Ratio , Female , Hepatitis A Vaccines/administration & dosage , Hepatitis A Vaccines/adverse effects , Hepatitis B Vaccines/administration & dosage , Hepatitis B Vaccines/adverse effects , Humans , Influenza Vaccines/administration & dosage , Influenza Vaccines/adverse effects , Male , Middle Aged , Pneumococcal Vaccines/administration & dosage , Pneumococcal Vaccines/adverse effects , Viral Load , Young Adult
7.
Eur J Clin Microbiol Infect Dis ; 29(7): 749-54, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20432051

ABSTRACT

This retrospective analysis examined the pneumococcal serotype distribution of acute otitis media in Germany from 1995 to 2007. Data from the German National Reference Centre for Streptococci included 512 cases of pneumococcal otitis media in children and adults. Infections were mainly seen in children aged <5 years, who represented 67.0% of all reported cases. Most isolates (86.7%) were from spontaneous ruptures of the tympanum; 11.1% of the isolates were from otogenic sepsis or meningitis. Serotype 19F was the leading serotype (21.5%); serotype 3 (13.9%) was also often encountered. In children aged <5 years, the 7-valent, 10-valent, and 13-valent pneumococcal conjugate vaccines covered 54.3%, 60.2%, and 84.6% of the serotypes, respectively. Reduced penicillin susceptibility (minimum inhibitory concentration >or=0.1 mg/l) was seen in 11.0% of strains; 22.4% of strains were resistant to macrolides. Although based on a very limited selection of acute otitis media isolates, this analysis provides an estimate of the pneumococcal serotypes responsible for otitis media in Germany and underscores the need for future prospective studies.


Subject(s)
Otitis Media/complications , Otitis Media/microbiology , Pneumococcal Infections/epidemiology , Pneumococcal Infections/microbiology , Sepsis/microbiology , Streptococcus pneumoniae/classification , Tympanic Membrane Perforation/microbiology , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Child , Child, Preschool , Female , Germany/epidemiology , Heptavalent Pneumococcal Conjugate Vaccine , Humans , Infant , Infant, Newborn , Male , Middle Aged , Pneumococcal Vaccines/immunology , Retrospective Studies , Serotyping , Streptococcus pneumoniae/isolation & purification , Young Adult
8.
Epidemiol Infect ; 138(9): 1353-8, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20092671

ABSTRACT

Pneumococcal meningitis is a subgroup of invasive pneumococcal disease with a case-fatality rate of up to 30% and long-term sequelae in more than 50% of cases in adults in developed countries. We aimed to determine risk factors for this particular form of pneumococcal disease. We conducted a prospective population-based laboratory study of invasive pneumococcal disease in adults in North-Rhine-Westphalia, Germany from February 2001 to August 2006. All isolates underwent serotyping and susceptibility testing at the National Reference Centre for Streptococci in Aachen, Germany. Data were analysed using multiple linear regression. A total of 1043 isolates from bacteraemia and 131 isolates from meningitis were included into the study. Serotype 23F and being female were independent risk factors for pneumococcal meningitis. Being 60 years and serotype 1 were associated with a reduced odds ratio. Season, penicillin and macrolide resistance were not statistically associated with CNS involvement.


Subject(s)
Pneumococcal Infections/microbiology , Adolescent , Adult , Aged , Female , Germany/epidemiology , Humans , Linear Models , Male , Meningitis, Pneumococcal/epidemiology , Meningitis, Pneumococcal/microbiology , Microbial Sensitivity Tests , Middle Aged , Pneumococcal Infections/epidemiology , Prospective Studies , Risk Factors , Seasons , Serotyping , Sex Factors , Streptococcus pneumoniae/classification , Streptococcus pneumoniae/isolation & purification
9.
Clin Microbiol Infect ; 16(3): 295-8, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19519840

ABSTRACT

This is the first study concerning the molecular epidemiology of group A streptococcus in Serbia and includes 145 isolates from patients with various infections during the period 2001-2007. The emm types, superantigen profile and susceptibility pattern were determined. Among 31 emm types identified, the most prevalent were emm 6, emm 12, emm 1, and emm 58. All isolates showed uniform antimicrobial susceptibility to all tested antibiotics, with the exception of tetracycline and erythromycin (41% and 0.7% resistant strains, respectively). Significant heterogeneity of emm types was found, with a high frequency of emm 6 and emm 58, as well as a considerable prevalence of tetracycline resistance, and a low level of macrolide resistance.


Subject(s)
Antigens, Bacterial/genetics , Bacterial Outer Membrane Proteins/genetics , Carrier Proteins/genetics , Polymorphism, Genetic , Streptococcal Infections/epidemiology , Streptococcal Infections/microbiology , Streptococcus pyogenes/classification , Streptococcus pyogenes/genetics , Anti-Bacterial Agents/pharmacology , Antigens, Bacterial/analysis , DNA Fingerprinting , DNA, Bacterial/genetics , Female , Genotype , Humans , Male , Microbial Sensitivity Tests , Molecular Epidemiology , Serbia/epidemiology , Streptococcus pyogenes/isolation & purification , Superantigens/analysis
10.
Clin Microbiol Infect ; 15(11): 1008-12, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19681946

ABSTRACT

A laboratory-based surveillance study of adult invasive pneumococcal disease was conducted in North-Rhine Westphalia, Germany's most populous federal state, with approximately 18 million inhabitants. Invasive isolates (n = 519) were obtained between 2003 and 2006, before the general recommendation for vaccination of German children <2 years with the pneumococcal conjugate vaccine was issued at the end of July 2006. Penicillin G resistance was observed in 5% of meningitis cases. In the non-meningitis group, only intermediately resistant strains were detected (0.4%). Intermediate resistance to cefotaxime occurred both in meningitis cases (1.7%) and non-meningitis cases (0.4%). Non-susceptibility rates (intermediate resistance and resistance) were 16.2% for macrolides, 10.9% for trimethoprim-sulphamethoxazole, 5.0% for tetracycline, 3.9% for clindamycin, and 0.4% for levofloxacin. All isolates were susceptible to amoxycillin (non-meningitis) and telithromycin. The leading serotypes were serotypes 14 (14.3%), 7F (9.4%), 3 (9.2%), 4 (8.7%) and 1 (8.1%). Serotype coverage for the seven-valent conjugate vaccine was 43.9%. For the ten-valent and 13-valent vaccines (in development), the coverages were 61.8% and 76.7%, respectively. The 23-valent polysaccharide vaccine had a coverage of 91.1%.


Subject(s)
Pneumococcal Infections/epidemiology , Pneumococcal Infections/microbiology , Pneumococcal Vaccines/immunology , Streptococcus pneumoniae/classification , Streptococcus pneumoniae/isolation & purification , Adolescent , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/pharmacology , Bacterial Typing Techniques , Drug Resistance, Bacterial , Germany/epidemiology , Humans , Infant , Male , Microbial Sensitivity Tests , Middle Aged , Pneumococcal Infections/prevention & control , Prevalence , Serotyping , Young Adult
12.
Clin Microbiol Infect ; 15 Suppl 3: 7-11, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19366363

ABSTRACT

Antibacterial resistance in pneumococci is increasing worldwide, primarily against beta-lactams and macrolides. Understanding the role played by molecular determinants of resistance, transformation and competence in the evolution of Streptococcus pneumoniae is important in addressing this trend. Data from the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin (PROTEKT) study indicate that about 40% of pneumococci display multidrug-resistant phenotypes (resistance to three or more antibiotics), with highly variable prevalence rates observed in different countries. Alterations in the structure of six penicillin-binding proteins (PBPs) have been described in S. pneumoniae (1a, 1b, 2x, 2a, 2b and 3), enabling resistance to beta-lactam antibiotics. Mechanisms conferring macrolide resistance include resistance mediated through the erm(B) gene, which results in macrolide-lincosamide-streptogramin B resistance, or through the mef(A) gene, which encodes an antibiotic efflux pump. Another variant, mef(E), is also expressed in S. pneumoniae; both mef(A) and mef(E) variants are associated with strains belonging to serotype 14. In addition to the selection pressure resulting from misuse of antibiotics, widespread vaccination programmes may contribute to changing pneumococcal epidemiology. Since the introduction of the seven-valent pneumococcal conjugate vaccine (PCV7), the rate of invasive pneumococcal disease due to PCV7 serotypes has declined significantly in many countries, but some countries have reported an increase in non-PCV7 serotypes. This phenomenon, termed 'replacement', is associated with certain pneumococcal serotypes or clones (e.g. serotype 19A). Whether novel 'vaccine escape recombinant' pneumococcal strains are emerging or changes in distribution are part of a secular cycle remains to be determined.


Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Resistance, Multiple, Bacterial , Pneumococcal Infections/epidemiology , Pneumococcal Infections/microbiology , Streptococcus pneumoniae/drug effects , Bacterial Typing Techniques , Heptavalent Pneumococcal Conjugate Vaccine , Humans , Macrolides/pharmacology , Pneumococcal Vaccines/immunology , Serotyping , Streptococcus pneumoniae/classification , Streptococcus pneumoniae/immunology , beta-Lactams/pharmacology
13.
Clin Microbiol Infect ; 13(12): 1173-8, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17850344

ABSTRACT

A nationwide voluntary laboratory-based surveillance study of invasive Streptococcus pyogenes (group A streptococcus; GAS) infections was conducted in Germany between 1996 and 2002. Demographical and clinical information concerning the patients was obtained from the medical files. Multiple logistic regression analysis was used to determine risk-factors for fatal outcome. Invasive isolates were obtained from 475 patients, with 251 (52.8%) of the isolates cultured from blood. The most frequent emm types were emm1 (36.4%), emm28 (8.8%) and emm3 (8%). The speA, speC and ssa genes were present at variable frequencies in different emm types. The highest frequencies of speA and speC were found in emm1 (speA, 93.6%) and emm4 (speC, 94.7%), respectively. The estimated annual incidence of invasive GAS disease for 1997-2002 was 0.1 cases/100 000 individuals. This apparently low incidence rate might be explained by the voluntary nature of the surveillance system, resulting in relatively few cases being referred to the laboratory. Complete clinical information was available for 165 cases. The overall case fatality rate was 40.6%, and was highest (65.2%) in the group aged 60-69 years. Shock, an age of >or=30 years and adult respiratory distress syndrome were predictors of a fatal outcome in a multiple logistic regression analysis. Overall, 6.7% of the cases were considered to be nosocomial, and nine cases of puerperal sepsis were observed. The study underscores the importance of invasive S. pyogenes disease in Germany.


Subject(s)
Streptococcal Infections/epidemiology , Streptococcal Infections/microbiology , Streptococcus pyogenes/classification , Streptococcus pyogenes/isolation & purification , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Antigens, Bacterial/genetics , Bacterial Outer Membrane Proteins/genetics , Bacterial Proteins/genetics , Carrier Proteins/genetics , Child , Child, Preschool , Community-Acquired Infections/microbiology , Cross Infection/microbiology , Exotoxins/genetics , Female , Germany/epidemiology , Humans , Incidence , Infant , Infant, Newborn , Logistic Models , Male , Membrane Proteins/genetics , Middle Aged , Risk Factors , Streptococcal Infections/mortality , Streptococcus pyogenes/genetics
14.
Eur J Clin Microbiol Infect Dis ; 26(8): 531-40, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17570001

ABSTRACT

Pneumococcal vaccine is effective in preventing invasive pneumococcal disease in adults >or=65 years of age, but it is not widely used in Western Europe. In this study, data from an earlier (1995) cost-effectiveness study on Belgium, France, Scotland, Spain, and Sweden are updated, and data on five new countries--Denmark, the UK (specifically, England and Wales), Germany, Italy and The Netherlands--are added. Epidemiological and economic variables specific for each country were used, and it was assumed that pneumococcal and influenza vaccines would both be administered during the same physician visit. In the base-case analyses, the cost-effectiveness ratios ranged from euro 9239 to euro 23,657 per quality-adjusted life-year. Because the incidence and mortality of invasive pneumococcal disease were underestimated in most countries, a country-by-country analysis was performed, assuming an incidence of 50 cases per 100,000 population and mortality rates of 20, 30 and 40%. For a mortality of 20%, the cost-effectiveness ratios ranged from euro 4,778 to euro 17,093, and for a mortality of 30%, they ranged from euro 3,186 to euro 11,395. Pneumococcal vaccination to prevent invasive pneumococcal disease in elderly adults was very cost-effective in all 10 countries. This evidence justifies the wider use of the vaccine in Western Europe.


Subject(s)
Health Care Costs/statistics & numerical data , Pneumococcal Vaccines/economics , Pneumonia, Pneumococcal/economics , Pneumonia, Pneumococcal/prevention & control , Aged , Aged, 80 and over , Cost-Benefit Analysis , Europe/epidemiology , Humans , Pneumonia, Pneumococcal/epidemiology
15.
Eur Respir J ; 30(3): 517-24, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17537775

ABSTRACT

Easily performed prognostic rules are helpful for guiding the intensity of monitoring and treatment of patients. The aim of the present study was to compare the predictive value of the sepsis score and the Confusion, Respiratory rate (> or =30 breaths.min(-1)), Blood pressure (systolic value <90 mmHg or diastolic value < or =60 mmHg) and age > or =65 yrs (CRB-65) score in 105 patients with community-acquired pneumococcal pneumonia. In addition, the influence of timing of the antimicrobial treatment on outcome was investigated. The sepsis and the CRB-65 scores were used to allocate patients to subgroups with low, intermediate and high risk. Comparable, highly predictive values for mortality were found for both scores (sepsis score versus CRB-65): 1) low-risk group, 0 versus 0%; 2) intermediate-risk group, 0 versus 8.6%; 3) high-risk group, 30.6 versus 40%, with an area under the curve of 0.867 versus 0.845. Patients with ambulatory antibiotic pre-treatment had less severe disease with a lower acute physiology score, lower white blood cell count and a faster decline of C-reactive protein levels. No pre-treated patient died. In summary, both scores performed equally well in predicting mortality. The prediction of survival in the intermediate-risk group might be more accurate with the sepsis score. Pre-hospital antibiotic treatment was associated with less severe disease.


Subject(s)
Community-Acquired Infections/diagnosis , Pneumonia, Pneumococcal/diagnosis , Sepsis/diagnosis , Severity of Illness Index , APACHE , Adult , Age Factors , Aged , Aged, 80 and over , Ambulatory Care , Anti-Bacterial Agents/therapeutic use , C-Reactive Protein/metabolism , Community-Acquired Infections/classification , Community-Acquired Infections/drug therapy , Community-Acquired Infections/mortality , Confusion/diagnosis , Female , Humans , Hypotension/diagnosis , Leukocyte Count , Male , Middle Aged , Pneumonia, Pneumococcal/classification , Pneumonia, Pneumococcal/drug therapy , Pneumonia, Pneumococcal/mortality , Premedication , Prognosis , Respiration Disorders/diagnosis , Risk Assessment , Sepsis/classification , Sepsis/drug therapy , Sepsis/mortality , Survival Analysis
16.
Clin Microbiol Infect ; 13(4): 363-8, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17359319

ABSTRACT

A population-based nationwide surveillance of antibiotic resistance associated with invasive pneumococcal disease (IPD) in children and adolescents (aged<16 years) was performed in Germany between 1997 and 2004. In total, 1517 isolates were collected, of which 5.1% and 1.1% were intermediately- or fully-resistant, respectively, to penicillin G. During the 8-year study period, an increase in resistance to both penicillin G and erythromycin A was observed, and the frequency of isolates exhibiting reduced susceptibility to penicillin G or erythromycin A increased from 1.4% and 11.1%, respectively, in 1997, to 8.7% and 29.0%, respectively, in 2004. Among the penicillin non-susceptible pneumococcal isolates, serotypes 14 (24.5% of isolates), 23F (16.0%) and 6B (16.0%) were found most frequently. Multilocus sequence typing of 58 (62%) penicillin G non-susceptible isolates revealed that sequence type (ST) 156 (Spain9V-3 clone) and its single-locus variant ST 557 were widespread in Germany. Moreover, 17 new penicillin G non-susceptible STs were defined for the first time. The study illustrated the genetic heterogeneity of antibiotic-resistant pneumococcal isolates in Germany.


Subject(s)
Penicillin Resistance , Pneumococcal Infections/microbiology , Streptococcus pneumoniae/drug effects , Streptococcus pneumoniae/genetics , Adolescent , Child , Child, Preschool , Humans , Infant , Infant, Newborn , Microbial Sensitivity Tests , Pneumococcal Infections/epidemiology , Pneumococcal Vaccines/immunology , Sequence Analysis, DNA , Serotyping , Streptococcus pneumoniae/classification , Vaccination
17.
J Clin Microbiol ; 45(2): 666-7, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17122015

ABSTRACT

Globicatella sanguinis is a very rare isolate in clinical samples. We present a case of meningitis in a 69-year-old female patient after implantation of an external left ventricular drainage due to a hydrocephalus. She recovered after antibiotic treatment with ceftriaxone.


Subject(s)
Gram-Positive Bacterial Infections/microbiology , Gram-Positive Cocci/classification , Gram-Positive Cocci/isolation & purification , Meningitis, Bacterial/microbiology , Ventriculoperitoneal Shunt/adverse effects , Aged , Female , Gram-Positive Cocci/genetics , Humans
18.
Laryngorhinootologie ; 85(4): 291-8; quiz 299-300, 2006 Apr.
Article in German | MEDLINE | ID: mdl-16615030

ABSTRACT

Streptococcus pneumoniae is a leading cause of bacterial pneumonia, meningitis, sinusitis, and acute otitis media in children and adults worldwide. Especially in the age group of < 2 years the incidence of invasive pneumococcal is high. The vulnerability of children to S. pneumoniae can also be demonstrated by the high rate of sequelae (> 20 % in Germany) and the high mortality (7.5 %) in pneumococcal meningitis. A 7-valent pneumococcal conjugate vaccine that was shown to be highly efficacious in preventing invasive pneumococcal disease in infants in the USA was licensed in Europe in 2001. It is expected that broad usage of the vaccine would reduce the incidence of invasive pneumococcal disease and the levels of pneumococcal resistance significantly.


Subject(s)
Meningitis, Pneumococcal/prevention & control , Otitis Media/prevention & control , Pneumococcal Infections/prevention & control , Pneumococcal Vaccines/administration & dosage , Pneumonia, Pneumococcal/prevention & control , Sinusitis/prevention & control , Vaccines, Conjugate/administration & dosage , Adolescent , Adult , Child , Child, Preschool , Drug Approval/legislation & jurisprudence , Germany , Humans , Infant , Treatment Outcome
19.
Infection ; 34(1): 22-5, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16501898

ABSTRACT

BACKGROUND: Enterococci possess capsular polysaccharide antigens that are the targets of opsonic antibodies. These antibodies are potential candidates for development as immunotherapy. MATERIAL AND METHODS: The present study analyzes the distribution of four capsular serotypes within a collection of 157 isolates of Enterococcus faecalis from four countries with different sites of clinical infection. RESULTS: By using a capsular polysaccharide-specific ELISA, 42% of the isolates were grouped into one of four serogroups, and another 9% showed cross-reactivity between two serotype-specific sera. Heterogeneity of serotype distribution by both geographical origin and infection site was observed. CONCLUSION: Half of the strain collection could be typed with four serotype-specific sera. No serotype from a given country or infection site clearly predominated.


Subject(s)
Bacterial Capsules/immunology , Enterococcus faecalis/classification , Gram-Positive Bacterial Infections/epidemiology , Bacterial Typing Techniques , Enterococcus faecalis/isolation & purification , Enzyme-Linked Immunosorbent Assay , Germany/epidemiology , Gram-Positive Bacterial Infections/microbiology , Humans , Italy/epidemiology , Japan/epidemiology , Organ Specificity , Serotyping , United States/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...